Action Against Cancer is privileged to have the following scientists and clinicians on its Scientific Advisory Board:
Professor Heinz-Josef Lenz
Director for Clinical Research and Co-Head of the GI Cancers Program, USC Norris Comprehensive Cancer Center, Professor of Medicine and Preventative Medicine, Keck School of Medicine, University of Southern California
Heinz-Josef Lenz, M.D. is a professor in the Departments of Medicine and Preventive Medicine in Keck School of Medicine's oncology division. He is the Director of Clinical Research of the USC/Norris Comprehensive Cancer Center, is chair of the GI Oncology Program and is the co-director of the Colorectal Center. He also serves as the scientific director of the Cancer Genetics Unit. Professor Lenz is co-chair of the Southwest Oncology Group's Gastrointestinal (SWOG GI) committee, chair of translational medicine of the SWOG GI committee, member of the National Cancer Institute (NCI) GI Steering Committee and member of the NCI translational medicine committee. He serves on several editorial boards as well as on national and international advisory boards. He has published over 120 peer reviewed papers.
Professor Jacqui Shaw
Professor of Translational Cancer Genetics, University of Leicester
Professor Jacqui Shaw's research has focussed on analysis of circulating free DNA (cfDNA) isolated from blood plasma for detection and monitoring of breast cancer. In collaboration with Professor RC Coombes at Imperial College she leads an integrated programme of clinical and translational research between the two universities. Her expertise includes molecular pathology, translational research and cell and molecular biology techniques including qPCR, microarrays, invasion, proliferation and migration assays.
Dr Abby Siegel
Assistant Professor, Department of Medicine, Columbia University Medical Center, New York
Dr Abby Siegel is medical oncologist who focuses on gastrointestinal cancers. She treats patients primarily with liver, biliary, and colon cancers. Dr Siegel also performs research related to novel therapeutics and predictive and prognostic biomarkers of response, primarily in patients with liver cancer. She currently holds a K12 award from the National Institute of Health (NIH). She is on the SWOG GI Steering Committee, and was recently appointed to the ASCO Scientific Program Committee to help set the clinical trials agenda for patients with upper GI malignancies nationally.